RGEN — REPLIGEN CORP

—
Nasdaq · Health Care · Biotechnology · CIK 730272 ·
Last close
$162.18
Market Cap
$10.30B
52W High
$198.87
52W Low
$100.99
ADV30
1,243,725
Next earnings
2026-10-27

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 204,128,000 110,037,000 19,002,000 5,008,000 2,950,180,000 606,783,000 838,148,000
Mar 2026 194,255,000 108,284,000 17,290,000 8,333,000 2,930,772,000 582,650,000 825,309,000
Dec 2025 197,913,000 103,831,000 16,348,000 13,287,000 2,949,699,000 566,021,000 843,570,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$134,864,000
Investing CF
$-222,604,000
Financing CF
$-11,787,000
CapEx
$-24,711,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.21
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$469,589,000
Inventory
$186,604,000
Receivables
$157,710,000
ST Investments
$203,666,000
EBIT TTM
$74,300,000
Pretax Income TTM
$52,150,000
Interest Exp TTM
$22,150,000
Analysts
18

Yahoo Snapshot (yfinance, live)

Total Revenue
$805,609,984
EBITDA
$143,498,000
Free Cash Flow
$111,584,000
Enterprise Value
$9,860,477,952
Total Cash
$862,979,008
Total Debt
$692,241,024
Shares Out
63,490,365
Trailing EPS
$-0.21
Book Value
$36.90
ROE
-0.6%
ROA
1.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 738,256,000 41,560,000 48,894,000 2,949,699,000 843,570,000 2,106,129,000 117,417,000
Dec 2024 634,439,000 -31,923,000 -25,514,000 2,829,666,000 856,948,000 1,972,718,000 175,394,000
Dec 2023 632,362,000 17,134,000 35,596,000 2,831,185,000 866,340,000 1,964,845,000 113,918,000
Dec 2022 801,536,000 195,941,000 185,959,000 2,531,600,000 620,900,000 1,910,700,000 172,083,000

TTM Snapshot

Revenues TTM
$785,101,000
NetIncome TTM
$41,539,000
OpCashFlow TTM
—
Assets (Latest)
$2,950,180,000
Forward EPS
$2.65

Max Pain — expiry 2026-12-18

max pain strike: $160.00 · spot: $172.67 · call oi: 1,889 · put oi: 4,060
Expected Move to 2026-12-18: ±$19.80 (11.47%) — implied range $152.87 – $192.47 · ATM straddle on $175.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
QGEN QIAGEN N.V. $10.27B $49.75 —
KYMR Kymera Therapeutics, Inc. $10.37B $121.52 —
HALO HALOZYME THERAPEUTICS, INC. $10.94B $95.97 —
PCVX Vaxcyte, Inc. $9.40B $59.40 —
TECH BIO-TECHNE Corp $11.41B $72.63 —

News headlines (Yahoo Finance, 1h cache)

Repligen (RGEN) Stock Looks Fairly Valued As Cash Flow Growth Matters
2026-11-16 23:19 · Yahoo
What iShares Russell 2000 Index Fund (IWM) Bought: Jackson Leads on Nov. 5
2026-11-09 11:05 · Yahoo
Repligen: 3 Key Takeaways for Long-Term Investors
2026-11-05 16:50 · Yahoo
Repligen Corporation to Present at Jefferies Global Healthcare Conference
2026-11-04 12:00 · Yahoo
RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook
2026-11-01 02:19 · Yahoo
5 must-read analyst questions from Repligen’s Q3 earnings call
2026-10-31 14:35 · Yahoo
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
2026-10-30 10:00 · Yahoo
Repligen Corporation (RGEN) Surges on Revenue Beat and Raised Full-Year Organic Outlook
2026-10-28 15:09 · Yahoo
Repligen Corporation (RGEN) Benefits From Biotech Momentum and Strong Earnings
2026-10-28 14:14 · Yahoo
Repligen (RGEN) Could Be 12% Undervalued As Record Revenue Lifts Guidance
2026-10-28 01:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.